[go: up one dir, main page]

MX2011007192A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2011007192A
MX2011007192A MX2011007192A MX2011007192A MX2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
bortezumib
containing pharmaceutical
composition
yrazine
Prior art date
Application number
MX2011007192A
Other languages
English (en)
Inventor
Subhas Balaram Bhowmick
Alok B Namdeo
N Subramanian
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2011007192A publication Critical patent/MX2011007192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica parenteral que comprende cantidades terapéuticamente efectivas de ácido N-(2-pirazina) carbonil-L-fenilalanina-L-leucina borónico o sus sales o sus derivados y trometamina en donde la composición es estable.
MX2011007192A 2009-01-09 2010-01-08 Composicion farmaceutica. MX2011007192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN58MU2009 2009-01-09
PCT/IN2010/000015 WO2010089768A2 (en) 2009-01-09 2010-01-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2011007192A true MX2011007192A (es) 2011-10-04

Family

ID=42542466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007192A MX2011007192A (es) 2009-01-09 2010-01-08 Composicion farmaceutica.

Country Status (10)

Country Link
US (1) US9095514B2 (es)
EP (1) EP2379077A4 (es)
JP (1) JP5689816B2 (es)
KR (1) KR20110114562A (es)
CN (1) CN102292086B (es)
AU (1) AU2010211981A1 (es)
CA (1) CA2748921A1 (es)
EA (1) EA201170921A1 (es)
MX (1) MX2011007192A (es)
WO (1) WO2010089768A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547333B1 (en) 2010-03-18 2017-08-23 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
WO2013128419A2 (en) * 2012-03-02 2013-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
CN103720666B (zh) * 2013-12-16 2015-11-25 亿腾药业（泰州）有限公司 一种注射用硼替佐米冻干制剂的制备方法
WO2016001905A2 (en) * 2014-07-04 2016-01-07 Dr. Reddy’S Laboratories Limited Stable liquid ready-to-use injectable formulation of bortezomib
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
KR101807462B1 (ko) * 2017-03-09 2017-12-08 씨제이헬스케어 주식회사 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
JP7423028B2 (ja) * 2017-11-01 2024-01-29 日医工岐阜工場株式会社 ボルテゾミブを含有する凍結乾燥医薬組成物
US11986486B2 (en) 2020-11-02 2024-05-21 Spes Pharmaceuticals Inc. Aqueous compositions of bortezomib
WO2024246786A1 (en) * 2023-05-31 2024-12-05 Cumberland Pharmaceuticals Inc. Injectable guanfacine formulations and methods
KR20250097513A (ko) * 2023-12-21 2025-06-30 주식회사 삼양홀딩스 안정성이 향상된 보르테조밉 수용액제 및 그 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6699835B2 (en) * 2001-01-25 2004-03-02 The United States Of America As Represented By The Department Of Health And Human Services Formulation of boronic acid compounds
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
WO2006001956A2 (en) * 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2006001965A2 (en) 2004-05-24 2006-01-05 Abgenix, Inc. Reducing the risk of human anti-human antibodies through v gene manipulation
CN101795671A (zh) 2007-08-21 2010-08-04 阿尔扎公司 用于体内施用硼酸化合物的脂质体组合物

Also Published As

Publication number Publication date
WO2010089768A2 (en) 2010-08-12
EP2379077A2 (en) 2011-10-26
CN102292086A (zh) 2011-12-21
KR20110114562A (ko) 2011-10-19
EP2379077A4 (en) 2013-09-11
JP2012514633A (ja) 2012-06-28
EA201170921A1 (ru) 2012-01-30
JP5689816B2 (ja) 2015-03-25
CA2748921A1 (en) 2010-08-12
US9095514B2 (en) 2015-08-04
CN102292086B (zh) 2013-05-08
US20110275597A1 (en) 2011-11-10
WO2010089768A3 (en) 2010-11-04
AU2010211981A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
MX2011007192A (es) Composicion farmaceutica.
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
MY170935A (en) Neprilysin inhibitors
GEP20146202B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
TN2011000400A1 (en) Inhibitors of beta-secretase
MX354476B (es) Inhibidores de neprilisina.
EA201270216A1 (ru) Фармацевтический состав
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MY165087A (en) Neprilysin inhibitors
PH12014502733A1 (en) Neprilysin inhibitors
MX366149B (es) Inhibidores de neprilisina.
IN2014CN04530A (es)
GEP20146201B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
UA109281C2 (uk) Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль
IN2012DN02502A (es)
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
EA201400365A1 (ru) Новые тиопроизводные лактамов в качестве высокоактивных ингибиторов hdac и их применение в качестве лекарственных средств
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
NZ707366A (en) Novel histone deacetylase inhibitors and their use in therapy
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
EA201490573A1 (ru) Соединение бензотиазолона
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal